ReNeuron Group plc (RENE.L) LSE
Currency In GBp
- General
- Statistics
- Historical Data
- Profile
- Financials
ReNeuron Group plc
Address
Pencoed Business Park
Pencoed, CF35 5HY
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 20 3819 8400
Website
Sector
Healthcare
Industry
Biotechnology
Employees
26
First IPO Date
August 12, 2005
Key Executives
| Name | Title | Pay | Year Born |
| John David Sinden | Co-Founder | 103,000 | 1951 |
| John Michael Hawkins | Company Secretary, Chief Financial Officer & Director | 192,908 | 1966 |
| Iain Gladstone Ross | Executive Chairman | 430,000 | 1954 |
| Randolph Corteling | Chief Scientific Officer | 0 | N/A |
| Hadley Chilton | Secretary | 0 | N/A |
| Simon Dew | Chief Business Officer | 0 | N/A |
| Suzanne Hancock | Chief Operations Officer | 0 | N/A |
Description
Established in 1997 and headquartered in Pencoed, UK, ReNeuron Group plc focuses on the research, development, and commercialization of innovative cell-based therapies. The company is actively developing a CTX stem cell therapy candidate targeting stroke disability, which is currently at the partnering stage for distribution both within and outside China. Another significant pipeline asset is its human retinal progenitor cell therapy, now in Phase I/IIa clinical trials, designed to treat retinitis pigmentosa, a debilitating eye disease leading to blindness. Furthermore, ReNeuron is conducting pre-clinical investigations into CTX-derived exosomes, which are microscopic, information-carrying packages released by CTX cells. The firm also generates revenue through the licensing of its ReNcell products. Collaboratively, ReNeuron has partnered with University College London to explore the creation of immune cells from induced pluripotent stem cells for application in anti-cancer cell therapies.
